Latest Content
-
| Andrew R. Zolopa MD - 5/8/2013 |
1 comment / Last Comment: 5/20/2013 |
The OPTIONS trial suggested that some treatment-experienced patients may not need NRTIs, but how do you translate this to clinical practice?
-
Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, comment on the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting.
Faculty: Joel E. Gallant MD, MPH, Kathleen E. Squires MD, Andrew R. Zolopa MD
Released: 5/7/2013
-
In this CME-certified slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review the most clinically relevant data presented at the 2013 Conference on Retroviruses and Opportunistic Infections.
Faculty: Joseph J. Eron, Jr. MD, William G. Powderly MD, Kimberly Y. Smith MD, MPH
Released: 5/3/2013
-
| Eric S. Daar MD - 4/11/2013 |
3 comments / Last Comment: 4/25/2013 |
How would you manage antiretroviral therapy in this patient on an abacavir-containing regimen?
-
| David A. Wohl MD - 4/4/2013 |
2 comments / Last Comment: 5/1/2013 |
With the increased risk for acute HCV infection in HIV-infected MSM and improved treatments on the horizon, I’ve started to perform routine screening among my patient population.
-
| Eric S. Daar MD - 4/2/2013 |
7 comments / Last Comment: 5/15/2013 |
Antiretroviral agents differ substantially in their ability to penetrate the CNS. Should this influence selection of initial ART in patients with HIV-associated neurocognitive disease?
-
| W. David Hardy MD - 3/28/2013 |
6 comments / Last Comment: 4/30/2013 |
Does this report from CROI have implications for how we manage HIV-exposed infants?
-
In this downloadable slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review key studies on coinfection and comorbidities in HIV infection from the 2013 Conference on Retroviruses and Opportunistic Infections.
Date Posted: 3/22/2013
-
Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, highlight the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting.
Date Posted: 3/21/2013
-
| Eric S. Daar MD - 3/21/2013 |
1 comment / Last Comment: 4/23/2013 |
Although PrEP can be effective in preventing HIV acquisition, the latest data from CROI further underscore the critical importance of adherence in determining efficacy.
|
Filter Content By
CCO Live Meetings- There are currently no events open for registration. Please check back later.
|